Opinion|Videos|October 28, 2023
Role of CAR-T Therapy in R/R Follicular Lymphoma
An overview of the evolving role of CAR-T therapy in patients with relapsed or refractory follicular lymphoma.
Advertisement
Episodes in this series
Advertisement
Related to this article
In a phase 2 trial, orelabrutinib plus sintilimab yielded a 60.7% overall response rate in relapsed/refractory primary CNS lymphoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Predicting Severe Immune-Related Toxicities in Lung Cancer Immunotherapy
2
Outpatient Treatment-Related Toxicity After Hospital Discharge Among Patients Receiving Lifileucel for Advanced Melanoma
3
CD19 CAR T Cell Therapy for Treatment-Refractory Seropositive Rheumatoid Arthritis: A Phase 1 Trial
4
Recapping GI Cancer at ESMO 2026: Standout Data From Phase 1 to Phase 3
5